Orchestra BioMed Holdings, Inc. OBIO
5.68 USD +0.06 (+1.07%)
At closeNov 6, 2026, 4:27 PM EST
5.68 0.00 0.00%
After hours · Nov 6, 4:27 PM ET
5.14 Day range 6.04
3.46 52-week range 6.50
- YTD
- +36.87%
- 1 year
- +49.08%
News
globenewswire.com Orchestra BioMed Announces Pricing of Public Offering NEW HOPE, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact…
benzinga.com Orchestra BioMed Commences Common Stock Offering; Terms Not Disclosed Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) ("Orchestra BioMed" or the "Company"), a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers TransMedics Group (NASDAQ:TMDX) stock rose 17.6% to $81.16 during Thursday's after-market session. The company's market cap stands at $2.5 billion. The company's, Q3 earnings came out today.
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Pomdoctor (NASDAQ:POM) shares rose 25.6% to $1.47 during Friday's after-market session. The market value of their outstanding shares is at $8.3 million. GeneDx Holdings (NASDAQ:WGS) shares…
benzinga.com This Copart Analyst Turns Bullish; Here Are Top 2 Upgrades For Friday Analysts upgraded Copart, Orchestra BioMed, Illumina, Martin Marietta Materials and Waters, raising their price targets.
benzinga.com Crude Oil Surges 6%; Macy’s Shares Fall After Q2 Results U.S. stocks fell Thursday as the Dow dropped 300+ points; Macy’s slid on weak guidance, while oil rose and producer prices accelerated.
benzinga.com Wealthfront, Orchestra Biomed, AeroVironment And Other Big Stocks Moving Higher On Thursday U.S. stocks fell, but Wealthfront surged 6.6% after beating Q2 earnings and revenue estimates; Orchestra Biomed, Clover Health and AeroVironment also rose.
benzinga.com This Meta Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday Analysts upgraded SFNC, OBIO, and more.
benzinga.com BTIG Upgrades Orchestra BioMed Hldgs to Buy, Announces $10 Price Target BTIG analyst Marie Thibault upgrades Orchestra BioMed Hldgs (NASDAQ:OBIO) from Neutral to Buy and announces $10 price target.
benzinga.com Piper Sandler Reiterates Overweight on Orchestra BioMed Hldgs, Raises Price Target to $10 Piper Sandler analyst Matt O'Brien reiterates Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Overweight and raises the price target from $9 to $10.
benzinga.com Orchestra BioMed Hldgs Q2 EPS $(0.38) Misses $(0.37) Estimate, Sales $88.000K Miss $121.400K Estimate Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.37) by 2.7 percent. This is a 24 percent increase over losses of…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session - benzinga.com B. Riley Securities Maintains Buy on Orchestra BioMed Hldgs, Lowers Price Target to $10 B. Riley Securities analyst Kyle Bauser maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and lowers the price target from $12 to $10.
benzinga.com HC Wainwright & Co. Reiterates Buy on Orchestra BioMed Hldgs, Maintains $10 Price Target HC Wainwright & Co. analyst Yi Chen reiterates Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and maintains $10 price target.
benzinga.com Barclays Maintains Overweight on Orchestra BioMed Hldgs, Raises Price Target to $13 Barclays analyst Matt Miksic maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Overweight and raises the price target from $12 to $13.
benzinga.com Orchestra BioMed Hldgs Q1 EPS $(0.33) Beats $(0.41) Estimate, Sales $110.000K Miss $190.750K Estimate Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.41) by 19.51 percent. This is a 32.65 percent increase over losses…- benzinga.com Orchestra BioMed Plans To Complete Enrollment In Its BACKBEAT Study Of Atrioventricular Interval Modulation Therapy By End Of Q3; Plans To Submit Primary Endpoint Data With Medtronic In Q2 Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with…
- benzinga.com Orchestra BioMed Receives $15M Payment From Ligand Pharma Under Previously Disclosed Revenue Participation Right Purchase And Sale Agreement $15 million payment fulfills previously scheduled tranche under royalty-based financing agreement, bringing total capital received from Ligand to $40 million to date in exchange for tiered royalty…
- benzinga.com Orchestra BioMed Receives $20M Investment From Medtronic Under Previously Announced Strategic Financing Agreement Payment fulfills previously disclosed funding commitment of $20 million and supports planned completion of the BACKBEAT Global Pivotal Trial ("BACKBEAT Trial") evaluating Atrioventricular Interval…
benzinga.com Orchestra BioMed Announces Second FDA Breakthrough Device Designation For AVIM Therapy Specific To Patients With Uncontrolled Hypertension Despite Use Of Medications, Along With An Indication For A Pacemaker Together, the two BDDs for AVIM Therapy cover indications that encompass both the broader population of patients with uncontrolled hypertension despite medication and increased cardiovascular risk as…- benzinga.com Orchestra BioMed Hldgs Q4 EPS $0.26 Beats $(0.39) Estimate, Sales $30.917M Beat $878.600K Estimate Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly earnings of $0.26 per share which beat the analyst consensus estimate of $(0.39) by 166.16 percent. This is a 160.47 percent increase over…
- benzinga.com Orchestra BioMed Anticipates Up To $21M In Cash Proceeds From Haemonetics Regarding Vivasure Acquisition Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing…
benzinga.com Assessing Orchestra BioMed Hldgs: Insights From 4 Financial Analysts - benzinga.com Barclays Maintains Overweight on Orchestra BioMed Hldgs, Raises Price Target to $12 Barclays analyst Matt Miksic maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Overweight and raises the price target from $11 to $12.
- benzinga.com TD Cowen Initiates Coverage On Orchestra BioMed Hldgs with Buy Rating, Announces Price Target of $15 TD Cowen analyst Joshua Jennings initiates coverage on Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy rating and announces Price Target of $15.
- benzinga.com Chardan Capital Maintains Buy on Orchestra BioMed Hldgs, Maintains $20 Price Target Chardan Capital analyst Keay Nakae maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and maintains $20 price target.
- benzinga.com Barclays Maintains Overweight on Orchestra BioMed Hldgs, Lowers Price Target to $11 Barclays analyst Matt Miksic maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Overweight and lowers the price target from $12 to $11.
- benzinga.com Orchestra BioMed Hldgs Q3 EPS $(0.40) Beats $(0.42) Estimate, Sales $861.000K Beat $757.600K Estimate Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.42) by 5.21 percent. This is a 2.44 percent increase over losses…
- benzinga.com Orchestra BioMed Enters $30M Agreement With Terum To Treat Coronary Artery Disease Globally Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with…
- benzinga.com Orchestra BioMed Announces First Patient Enrollments In Virtue SAB In Treatment Of Coronary ISR Trial Orchestra BioMed's Virtue® Sirolimus AngioInfusionTM Balloon ("Virtue SAB") is the first non-coated drug-eluting balloon system designed to deliver a large liquid dose of proprietary extended-release…
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Orchestra Biomed To Present Data Summary Supporting Transformative Potential Of AVIM Therapy In Management Of Hypertensive Heart Disease At Georgia Innovation Summit In Tbilisi Presentation to provide comprehensive overview of AVIM Therapy clinical evidence demonstrating the potential to halt the progression of hypertensive heart diseaseOrchestra BioMed and Medtronic…- benzinga.com OBIO Highlights Long-Term Durability Of AVIM Therapy In Major Clinical Publications And HRX 2025 Presentation Blog Post - OBIO | AVIM therapy: Durability, Reversibility, and Reproducibility of Effect September 22, 2025 September 22, 2025 | Fellow Shareholders: Recent clinical announcements related to our…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com Why Gorilla Technology Group Shares Are Trading Lower By 25%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares jumped 104.5% to $0.1916.
- benzinga.com Why Clearmind Medicine Shares Are Trading Lower By 53%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Gainers First Wave BioPharma, Inc. (NASDAQ: FWBI) shares jumped 89.5% to $0.8243 after the company announced license agreement for capeserod from Sanofi.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday During Wednesday's trading, 103 companies set new 52-week lows.
- benzinga.com Why Avid Bioservices Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Gainers Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) shares climbed 422% to $0.5572 after the company announced acquisition of Spyre Therapeutics and concurrent oversubscribed $210 million private…
- benzinga.com Why Tupperware Brands Shares Are Trading Lower By Over 40%? Here Are Other Stocks Moving In Monday's Mid-Day Session Gainers PLx Pharma Inc. (NASDAQ: PLXP) gained 128.2% to $0.2399 after dropping over 13% on Thursday.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For February 24, 2023
- benzinga.com Comfort Systems, Gannett, CommScope And Other Big Stocks Moving Higher On Thursday U.S. stocks traded slightly lower, with the Dow Jones dropping around 30 points on Thursday. Here are some big stocks recording gains in today’s session.